March 24, 2016By Alex Keown, BioSpace.com Breaking News Staff SOUTH PLAINFIELD, N.J. – Shares of PTC Therapeutics (PTCT) plunged in overnight trading Wednesday night after the company announced it was reducing its workforce by 18 percent following the rejection of its Duchenne muscular dystrophy (DMD) drug by the U.S. Food and Drug Administration. PTC […]
Respironics Inc. has agreed to pay $34.8 million to settle U.S. Department of Justice claims that it provided kickbacks in the form of free call center services to suppliers.
Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases March 23, 2016 06:59 AM Eastern Daylight Time NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the […]
Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead’s blockbuster cure for hepatitis C. After returning its verdict in favor of Merck on Tuesday, […]
Investors are not completely happy with Gilead Sciences’ share price, which is down about 10 percent from its starting point in 2015.
Janssen R&D and Genentech to initiate two studies to determine the safety and tolerability of daratumumab (Darzalex) and atezolizumab for multiple myeloma and solid tumor.
Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m Initiation of first clinical trials expected in 2017 March 22, 2016 02:24 AM Eastern […]
J. Michael Pearson is out at Valeant Pharmaceuticals and the company is looking for a new chief executive officer.
Helsinn and Eisai Inc. announced a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise.
ROCHESTER, Minn., March 18, 2016 /PRNewswire/ — Omnis Pharma, Inc. and Magnis Therapeutics, LLC, announced today their strategic merger to form Vyriad, a clinical-stage oncolytic immunovirotherapy development company. The combined companies’ product development pipeline encompasses multiple clinical-stage and late preclinical-stage products targeting a broad range of human cancer indications, including a Phase 1 development program partnered […]